U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07229144) titled 'OM336 in Seropositive Autoimmune Diseases' on Nov. 13.
Brief Summary: An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Sjogrens Disease
Idiopathic Inflammatory Myopathy (IIM)
Intervention:
DRUG: OM336
OM336 is an engineered bispecific antibody directed against BCMA and CD3
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ouro Medicines
Published by HT Digital Content Services with permiss...